NHS Dudley Health Economy Medicines Formulary
Home > 11 Eye > 11.8 Miscellaneous ophthalmic preparations > 11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment > Choroidal neovascularisation (pathological myopia) - ranibizumab NICE TAG TA298

Choroidal neovascularisation (pathological myopia) - ranibizumab NICE TAG TA298

1.1 Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/TA298

Site by Devopa
© Copyright 2019 NHS. All rights reserved.